Prognostic significance of the methylation of Wnt pathway antagonists—CXXC4, DACT2, and the inhibitors of sonic hedgehog signaling—ZIC1, ZIC4, and HHIP in head and neck squamous cell carcinomas by Jarosław Paluszczak et al.
ORIGINAL ARTICLE
Prognostic significance of the methylation of Wnt pathway
antagonists—CXXC4, DACT2, and the inhibitors of sonic
hedgehog signaling—ZIC1, ZIC4, and HHIP in head and neck
squamous cell carcinomas
Jarosław Paluszczak1 & Dorota Wiśniewska1 & Magdalena Kostrzewska-Poczekaj2 &
Katarzyna Kiwerska2 & Reidar Grénman3 & Daniela Mielcarek-Kuchta4 &
Małgorzata Jarmuż-Szymczak2
Received: 2 June 2016 /Accepted: 16 August 2016
# The Author(s) 2016. This article is published with open access at Springerlink.com
Abstract
Objectives Aberrations in Wnt and Shh signaling pathways
are related to the pathogenesis of head and neck carcinomas,
and their activation frequently results from epigenetic alter-
ations. This study aimed to assess the frequency of methyla-
tion of negative regulators ofWnt signaling:CXXC4,DACT2,
HDPR1, and FBXW11 and Shh signaling: HHIP, PTCH1,
SUFU, ZIC1, and ZIC4 and correlate it with clinicopatholog-
ical features in this group of patients.
Materials and methods Methylation-specific PCR was used
to detect gene promoter methylation, and real-time PCR was
used to assess gene expression level.
Results The analysis of the occurrence of gene promoter
methylation in head and neck carcinoma cell lines indicated
that CXXC4, DACT2, HHIP, ZIC1, and ZIC4 are methylated
in these tumors. These genes were further analyzed in tumor
sections from oral and laryngeal cancer patients. Gene meth-
ylation rate was higher in laryngeal tumors. The methylation
index in tumor samples correlated with the overall survival in
a subgroup of oral cancer patients who died of the disease.
Moreover, ZIC4 methylation correlated with lymph node in-
volvement in oral cancer patients.
Conclusions Our findings corroborate that the activation of
Wnt signaling in head and neck squamous cell carcinoma
(HNSCC) is related to epigenetic silencing of its negative
regulators. Moreover, the results indicate that the same mech-
anism of activation may operate in the case of Shh signaling.
Clinical relevance The methylation of ZIC4 may be consid-
ered a new prognostic marker in oral cavity and oropharyngeal
tumors. Further investigations should determine the diagnos-
tic significance of methylation of ZIC4, HHIP, and DACT2 in
head and neck carcinomas.
Keywords Head and neck cancer . DNAmethylation . Shh
pathway .Wnt pathway . ZIC4
Abbreviations
HNSCC Head and neck squamous cell carcinoma
LSCC Laryngeal squamous cell carcinoma
OSCC Oral squamous cell carcinoma
Introduction
Head and neck cancers consist approximately 6 % of all can-
cer cases in Poland with nearly six thousand new cases annu-
ally [1, 2]. Despite recent advancements in oncology, the five-
year survival rates in head and neck cancers have remained
unchanged and are estimated overall around 50–60 %. The
prognosis is much worse in the case of patients suffering from
more advanced (regional and distant) tumors. New therapeutic
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strategies and diagnostic markers are necessary for the im-
provement of treatment outcomes. The molecular biology of
head and neck squamous cell carcinomas (HNSCC) which are
the most prevalent type of head and neck malignancy is in-
creasingly well understood what currently forms the basis for
the search of both new biomarkers and novel chemotherapeu-
tic strategies. Among the many molecular aberrations ob-
served in HNSCC, changes in the activity of signaling path-
ways such as TGFβ, Ras/PI3K/AKT/mTOR, Notch, or NFκB
which are responsible for the regulation of cell proliferation,
migration, and cell death emerge as important factors associ-
ated with both the pathogenesis and progression of the disease
[3–5]. Recently, aberrations in the function of sonic hedgehog
(Shh) and canonical Wnt pathways have been also implicated
in the development of HNSCC.
Canonical Wnt signaling regulates the nuclear transloca-
tion of β-catenin. In unstimulated cells, β-catenin is seques-
tered in the cytoplasm by an inhibitory complex which con-
sists of axin, APC, casein kinase and glycogen synthase ki-
nase—GSK3β. In these conditions, β-catenin undergoes
phosphorylation and is targeted for proteasomal degradation.
The binding of Wnt ligands to membrane frizzled/LRP recep-
tors causes the destabilization of the inhibitory complex via
activation of disheveled and leads to the release of β-catenin
which enters the nucleus and binds to TCF/LEF transcription
factors. This stimulates the transcription of various genes re-
sponsible for cell cycle regulation and cell migration including
CCND1 (encoding cyclin D1), survivin, MMP-7 (encoding
matrix metalloproteinase 7), and c-Myc [6]. The precise regu-
lation of the pathway is also secured by the activity of a group
of proteins which antagonize the progression of the pathway
in a stage-specific manner. The activation of canonical Wnt
pathway is detected already in precancerous lesions [7, 8], and
its dysregulation may increase with tumor progression attrib-
uting to enhanced cancer cell migration and thus worse prog-
nosis [9–11]. The activation of Wnt signaling in HNSCC is
rarely the result of genetic mutations but usually occurs due to
the hypermethylation of genes encoding the negative regula-
tors of the pathway [12–15]. The methylation ofWnt pathway
antagonists such as SFRP1–5, DKK1–3, WIF1, DACH1, and
PPP2R2B has been frequently observed, and it was associated
with worse prognosis [15–18]. The biological importance of
Wnt dysregulation for the development of HNSCC is corrob-
orated by the fact that the growth of tongue cancer cells is
inhibited by the silencing of CTNNB1 gene which encodes
β-catenin [19].
Sonic hedgehog is another signaling pathway active in em-
bryonal and somatic stem cells which undergoes activation in
human cancers [20] and may have crosstalk with Wnt signaling.
The binding of Shh ligand to patched (PTCH1) protein relieves
the inhibition of smoothened (SMO)which is then able to relieve
the sequestration of a Gli1 transcription factor by a cytoplasmic
complex which includes SUFU (suppressor of fused homolog).
This subsequently induces Gli1 translocation to the nucleus
where it stimulates the expression of genes related to cell prolif-
eration and cell cycle regulation. Evidence for the implication of
Shh pathway dysregulation in the pathogenesis of HNSCC has
only recently started to accumulate [21–24]. Importantly, Shh
activation was associated with disease progression and worse
prognosis in oral squamous cell carcinoma (OSCC) [25].
Based on these findings, Shh signaling has been indicated as a
new therapeutic target in this tumor type [26]. Indeed, treatment
of HNSCC cells with Shh inhibitor cyclopamine suppressed cell
growth and enhanced the cytotoxic effects of cisplatin and doce-
taxel [27]. However, the molecular mechanisms leading to the
activation of Shh inHNSCChave not beenwell studied although
it is suggested that this may occur due to epigenetic changes [28].
The association between the dysregulation of Wnt and Shh
pathways and the pathogenesis of HNSCC implicates the pos-
sibility of therapeutic targeting HNSCC by modulating the
activity of these pathways. This however requires a thorough
understanding of the molecular mechanisms which lead to
pathway activation, and epigenetic mechanisms have emerged
as the possibly most important factor which attributes to this
phenomenon. Relatively, much is known about the effect of
epigenetic silencing of several negative regulators of Wnt
pathway on its activation in HNSCC although the studies have
focused only on few regulatory genes so far. On the other
hand, the contribution of epigenetic mechanisms to Shh acti-
vation in HNSCC has not been well studied and requires ex-
ploration. Most importantly, epigenetic silencing of negative
regulators of Wnt and Shh pathways may have diagnostic
significance. Thus, the aim of the present study was to assess
the frequency of methylation of the selected negative regula-
tors of Wnt signaling: CXXC4, DACT2, HDPR1 (DACT1),
and FBXW11 and Shh signaling: HHIP, PTCH1, SUFU,
ZIC1, and ZIC4 which were either rarely or never under study
in head and neck cancers previously and correlate it with clin-
icopathological features in a group of HNSCC patients.
Materials and methods
Cell lines
Thirty-six cell lines which were derived from squamous cell
carcinomas of the head and neck region at the University of
Turku, Finland [29] were analyzed. The characteristics of the
patients whose surgically removed tumor sections were used
for the establishment of the respective cell lines are presented
in Table 1.
Patients
The study group consisted of 42 patients with primary
oral/oropharyngeal squamous cell carcinoma (localized
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mostly in tongue or tonsils) and 30 patients with primary
laryngeal squamous cell carcinoma (LSCC) who were primar-
ily treated surgically at the Department of Otolaryngology and
Laryngological Oncology, Poznan University of Medical
Sciences. In the case of oral cancer patients, a tumor section
along with a fragment of macroscopically normal surgical
margin was obtained from each patient for analysis. Only
tumor sections which contained at least 80 % of cancer cells
were qualified for further investigation. Patient follow-up ob-
servation usually covered at least 3 years post-operation.
Eighteen OSCC and 12 LSCC patients died of the disease
during follow-up. The study was approved by the local ethics
committee at Poznan University of Medical Sciences. The
clinical characteristics of the study group are presented in
Table 2.
Methylation-specific PCR
DNA samples from the early passage cell lines and from a
clinical material were prepared using standard phenol/
Table 1 Characteristics of the
patients and the derived cell lines Name of
cell line








UT-SCC-4 F 43 Hypopharynx/
supraglottic larynx
T3N0M0 Neck met G2
UT-SCC-6A F 51 Supraglottic larynx T2N1M0 Larynx rec G1
UT-SCC-6B F 51 Supraglottic larynx T2N1M0 Neck met G1
UT-SCC-7 M 67 Skin (temporal region) T1N0M0 Neck met G2
UT-SCC-8 M 42 Supraglottic larynx T2N0M0 Larynx pri G1
UT-SCC-10 M 62 Tongue scc T1N0M0 Tongue pri G2
UT-SCC-
16A
F 77 Tongue scc T3N0M0 Tongue pri G3
UT-SCC-
16B
F 77 Tongue scc T3N0M0 Neck met G3
UT-SCC-17 M 65 Supraglottic larynx T2N0M0 Sternum met G3
UT-SCC-
19A
M 44 Glottic larynx T4N0M0 Larynx pri G2
UT-SCC-
19B
M 44 Glottic larynx T4N0M0 Larynx pri (per) G2
UT-SCC-
20A
F 58 Floor of mouth T1N0M0 Floor of mouth pri (per) G2
UT-SCC-
20B
F 58 Floor of mouth Floor of mouth resid G2
UT-SCC-22 M 79 Glottic larynx T1N0M0 Larynx rec G2
UT-SCC-23 M 66 Transglottic larynx T3N0M0 Larynx pri (per) G1
UT-SCC-
24A
M 41 Tongue scc T2N0M0 Tongue pri G2
UT-SCC-
24B
M 41 Tongue scc Neck met (per) G2
UT-SCC-29 M 82 Glottic larynx T2N0M0 Larynx pri G1
UT-SCC-34 M 63 Supraglottic larynx T4N0M0 Supraglottic
larynx
pri G1
UT-SCC-35 M 50 Glottic larynx T2N0M0 Larynx resid G2
UT-SCC-36 M 46 Floor of mouth T4N1M0 Floor of mouth pri G3
UT-SCC-38 M 66 Glottic larynx T2N0M0 Larynx pri G2
UT-SCC-45 M 76 Floor of mouth T3N1M0 Floor of mouth pri G3
UT-SCC-47 M 78 Floor of mouth T2N0M0 Floor of mouth pri G3
UT-SCC-56 M 62 Floor of mouth TxN2M0 Floor of mouth rec G2–G3
UT-SCC-58 M 63 Transglottic larynx T4N1M0 Neck met (skin) G1
UT-SCC-85 M 55 Tongue scc T3N0M0 Tongue floor of
mouth
rec G2
UT-SCC-90 M 35 Tongue scc T1N0M0 Floor of mouth rec/met G2
UT-SCC-100 M 70 Gingival scc rT3 Mucosae
bucchae
rec G3
UT-SCC-103 M 51 Glottic larynx T3N0M0 Larynx pri (per) G2
UT-SCC-104 M 80 Supraglottic larynx T1N2AM0 Neck met G2
UT-SCC-
106A
M 59 Glottic larynx T1AN0M0 Larynx pri G2
UT-SCC-
106B
M 59 Glottic larynx rT3N0M0 Larynx rec G3
UT-SCC-107 M 46 Supraglottic larynx T4N2CM0 Larynx pri G2
UT-SCC-108 M 68 Supraglottic larynx T2N0M0 Larynx pri G3
UT-SCC-116 M 60 Supraglottic larynx T4N1M0 Larynx pri G2
F female, M male, scc squamous cell carcinoma, pri primary, per persistent, rec recurrent, met metastasis, resid
residual
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chloroform extraction protocol. Methylation-specific PCR
(MSP) was used for the analysis of gene promoter methylation
[30]. Prior to amplification, all the DNA samples underwent
bisulfite conversion using an EZ DNA methylation Kit
(ZymoResearch, USA) according to manufacturer’s protocol.
Primer sequences for the analysis of CXXC4, FBXW11,
SUFU, ZIC1, and ZIC4 were designed using the MethPrimer
online software [31] and are presented in Table 3. Primer
sequences used for the analysis of DACT2, HDPR1, HHIP,
and PTCH1 were previously described [32–35]. All the
primers were obtained from the oligonucleotide synthesis fa-
cility at the Institute of Biochemistry and Biophysics, Polish
Academy of Sciences. DNA derived fromwhite blood cells of
healthy donors and fully methylated human genomic DNA
(Thermo Scientific, USA) were used as negative and positive
MSP controls, respectively. Moreover, samples of genomic
DNA extracted from early passage primary culture of human
oral keratinocytes and human tracheal epithelial cells
(ScienCell Research Laboratories, USA) were used as normal
controls for comparison. PCR reactions were performed in a
T100 thermal cycler (Bio-Rad Laboratories, USA) using HOT
FIREPol Polymerase (Solis BioDyne, Estonia). The amplifi-
cation protocol was as follows: initial enzyme activation for
15 min at 95 °C followed by 40 cycles of 95 °C for 30 s, X°C
for 30 s and 72 °C for 30 s, and the final elongation at 72 °C
for 5 min, where X stands for the appropriate annealing tem-
perature as described in Table 3. PCR products were resolved
on 2 % agarose gels in the presence of the Midori Green DNA
stain (Nippon Genetics, Japan) and subsequently visualized
under UV light illumination. The resulting electrophoregrams
were interpreted as previously [17]. In the case of the cell
lines, the presence of the band only in the reaction with the
starters specific for the unmethylated sequence was treated as
lack of gene methylation (U), whereas the presence of the
band only in the reaction with the starters specific for the
methylated sequence was treated as full gene methylation
(M). Partial methylation (M/U) was detected when bands were
observed in both reactions. Because DNA samples extracted
from tumor sections cannot be treated as derived from a rather
homogenous population of cancer cells (as in the case of cell
lines), thus a simplified interpretation was used. Gene meth-
ylation (M) was detected in each case when the band in the
reaction with the starters specific for the methylated sequence
was present. Lack of gene methylation (U) was detected in
each case when the band in the reaction with the starters spe-
cific for the methylated sequence was missing and only the
band in the reaction with the starters specific for the
unmethylated sequence was present.
Quantitative PCR
Standard phenol/guanidine thiocyanate extraction protocol
served for the preparation of total RNA samples from early
passage cell lines. An RNA sample isolated from first passage
primary oral keratinocytes (ScienCell Research Laboratories,
USA) was used as a calibrator in gene expression quantifica-
tion. All RNA samples were reverse transcribed using the
RevertAid First Strand cDNA Synthesis Kit (Thermo
Scientific) according to manufacturer’s protocol. Primer se-
quences for the analysis of the transcript level of CXXC4,
DACT2, and HHIP were designed using the Beacon
Designer software and further BLAST searched to minimize
non-specific binding. Each primer pair covered a region span-
ning two distinct exons. The sequences are listed in Table 4.
Quantitative real-time PCR reactions were performed in a
Chromo4 thermal cycler (Bio-Rad Laboratories, USA) using
the HOT FIREPol Eva Green qPCR Mix (Solis BioDyne,
Estonia). The amplification protocol was as follows: initial
enzyme activation for 15 min at 95 °C followed by 40–45 cy-
cles of 95 °C for 20 s, X°C for 20 s and 72 °C for 40 s, and the
final elongation at 72 °C for 5 min, where X stands for the
annealing temperature as described in Table 4. Subsequent
melting curve analysis allowed the confirmation of the pres-
ence of a single product. Measurements were performed in
duplicate, and mean values were normalized using PBGD
(porphobilinogen deaminase) as the reference gene. Relative
expression level was calculated with theΔΔCt method using
Table 2 Clinical characteristics of patients in the study group
OSCC LSCC
Age Range 28–84 39–79
Mean 57 57
Sex Female 4 2
Male 38 28









G histological stage G1 9 8
G2 26 21
G3 7 1
Overall survival time (months) Range 0–72 4–93
Mean 30 54
Tumor-related death 18 12
Other Recurrence 6 11
Metastasis 1 1
Second primary tumor 2 0
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the formula: RE = 2 [Ct(ref) − Ct(test) TUMOR]/2 [Ct(ref) − Ct(test)
normal keratinocytes].
Statistical analysis
The association between clinicopathological variables and the
occurrence of single gene methylation was analyzed using
chi-square or Fisher’s exact tests. The association between
clinicopathological variables and methylation index was ana-
lyzed using the Mann-Whitney U test or Kruskal-Wallis test.
The analysis of the association of single gene methylation
with overall survival timewas performed using the F-Cox test.
Multiple regression analysis allowed for the establishment of
the association between methylation index and overall surviv-
al time. All the analyses were performed using the
STATISTICA 10 software (StatSoft, Poland), and differences
between groups were considered significant when p ≤ 0.05.
Results
In the screening stage, the analysis of the occurrence of pro-
moter methylation of the studied genes in DNA samples de-
rived from head and neck squamous cell carcinoma cell lines
allowed for the identification of those genes which undergo
methylation in these tumors. No methylation was detected for
FBXW11, PTCH1, or SUFU while all the other genes showed
relatively low (DACT2) to high (ZIC1) frequency of methyl-
ation in the tested cell lines except HDPR1, which was only
partly methylated in two cell lines (Table 5). Representative
electrophoregrams are shown in Fig. 1. There was no statisti-
cally significant difference in the frequency of gene methyla-
tion between laryngeal and oral cavity and oropharyngeal car-
cinoma cell lines. Importantly, none of the genes was methyl-
ated in genomic DNA derived from normal oral keratinocytes
or tracheal epithelial cells indicating that the methylation of
Table 3 Sequences of the starters
used in methylation-specific PCR
designed using MethPrimer
Gene Sequence Ta
CXXC4 MF 5′ GGAGAGAGAGAGGAGAGATTTTTC 3′ 60 °C
MR 5′ ATAAAAACGCGAATCTATTATCGAT 3′
UF 5′ AGAGAGAGAGGGAGAGATTTTTTGG 3′ 56 °C
UR 5′ ATAAAAACACAAATCTATTATCAAT 3′
FBXW11 MF 5′ TAGGAAGTTAAGAGAAGTTAGTCGG 3′ 59 °C
MR 5′ CACTAAACGATAAACGTAAAACGTA 3′
UF 5′ TAGGAAGTTAAGAGAAGTTAGTTGG 3′ 59 °C
UR 5′ CACTAAACAATAAACATAAAACATA 3′
SUFU MF 5′ GTTTCGGGGAGTTTTATTTATC 3′ 60 °C
MR 5′ GAAAACCGAAAAAACAATCG 3′
UF 5′ GTTTTGGGGAGTTTTATTTATTGA 3′ 60 °C
UR 5′ AAACAAAAACCAAAAAAACAATCA 3′
ZIC1 MF 5′ TTTCGTTAAACGTTTATTCGTTTC 3′ 62 °C
MR 5′ CACCTAACCTCCTAAAAACCTACG 3′
UF 5′ TTTGTTAAATGTTTATTTGATTTTGT 3′ 54 °C
UR 5′ TCACCTAACCTCCTAAAAACCTACA 3′
ZIC4 MF 5′ CGGTTCGGTTAGGAAATTTATC 3′ 62 °C
MR 5′ AACCAAAAAAACGAAAAACGAC 3′
UF 5′ AGGTGGTTTGGTTAGGAAATTTATT 3′ 60 °C
UR 5′ AAAAACCAAAAAAACAAAAAACAAC 3′
M methylated, U unmethylated, F forward, R reverse, Ta annealing temperature
Table 4 The sequence of starters
used in real-time PCR analysis Gene Starter sequence Amplicon size Annealing T
CXXC4 F 5′ CACCTCCTCCTCCTTCCAC 105 bp 56 °C
R 5′ GCATTATCCTCCAACTGTTACAAC
DACT2 F 5′ CAGGCTTTTACGAGATGAG 89 bp 56 °C
R 5′ CAGCGAGGGAGAGATGTG
HHIP F 5′ TCCTATACCACCAACCAAGAAC 165 bp 59 °C
R 5′ TTGTCCTCCCAGATGCTTTC
PBGD F 5′ TCAGATAGCATACAAGAGACC 111 bp 56 °C
R 5′ TGGAATGTTACGAGCAGTG
F forward primer, R reverse primer
Clin Oral Invest
CXXC4, DACT2, HHIP, ZIC1, and ZIC4 does not appear in
normal epithelial cells. We also wanted to assess whether the
methylation of gene promoter regions under analysis correlat-
ed with their transcriptional activity. Therefore, we analyzed
the expression of those genes which showed differential meth-
ylation status among the cell lines (Fig. 2). The expression of
these genes in normal human oral keratinocytes (HOK) served
as the reference in quantification. The quantitation of the tran-
script level of CXXC4 and HHIP showed that full gene pro-
moter methylation correlated with decreased level of expres-
sion when compared to expression in normal oral
keratinocytes. The expression of these genes in cell lines
showing only partial methylation or lack of methylation was
not suppressed. This indicates that promoter methylation of
these genes is associated with loss of their expression in
HNSCC cells. Such an association was not observed in the
case of DACT2, where the transcript level was similar irre-
spective of its methylation status indicating that the methyla-
tion of the analyzed promoter region is not the decisive factor
in establishing transcription intensity.
Based on the findings that CXXC4, DACT2, HHIP,
ZIC1, and ZIC4 are methylated in HNSCC cell lines
and that their methylation is not present in normal oral
and tracheal epithelium, we further investigated the fre-
quency of methylation of these genes in laryngeal and
oral tumor samples and matched surgical margin sam-
ples of OSCC patients. Exemplary electrophoregrams
are shown in Fig. 3, and the summary of the results is
presented in Table 6. The rate of methylation of ZIC1,
ZIC4, HHIP, and DACT2 in tumors was very high,
while methylation of CXXC4 was low to moderate in
OSCC and LSCC. Laryngeal tumors showed generally
higher rates of gene methylation than oral cancers. Gene
methylation was detected in all LSCC samples. The
concurrent methylation of four genes was observed most
frequently (43.7 %) followed by the observation of con-
current methylation of all five genes (23.3 %). The
remaining cases showed the methylation of either three
(20 %) or two (10 %) genes. Thus, the mean methyla-
tion index (MI—number of methylated genes divided by
the number of all the tested genes) in LSCC samples
was high—0.78. The occurrence of gene methylation
was also highly prevalent among OSCC samples with
only three cases showing the lack of methylation of any
of the tested genes. Two OSCC cases showed the meth-
ylation of all five genes. The concurrent methylation of
three genes was observed most frequently (26.2 %)
followed by the concurrent methylation of two or four
genes (23.8 %) or the methylation of a single gene
(14.3 %). The mean methylation index in OSCC sam-
ples was 0.56. The frequency of methylation of the
analyzed genes in OSCC surgical margin samples was
lower than in the corresponding tumor samples what
was reflected by a lower MI value of 0.4. The analysis
of concordance (presence or lack of methylation in both
paired samples) or discordance (presence of methylation
in only one paired sample) of the results between paired
tumor and surgical margin in OSCC patients is present-
ed in Table 7. Most discordant results were associated
with the lack of gene methylation in the resection
margin.
The presence of gene methylation in tumor samples
did not correlate with histological grade or tumor size.
However, the presence of ZIC4 methylation in oral
tumors significantly correlated with lymph node inva-
sion (p = 0.041). The methylation of ZIC4 in tumors
did not correlate with the overall survival of patients
(Fig. 4) although there was a trend for an association
between ZIC4 methylation and shorter survival in
OSCC patients (p = 0.09088). Moreover, the MI value
in oral tumor samples moderately correlated with the
overall time of survival in the subgroup of 18 patients
who died of the disease (r = 0.46, p = 0.05). The
presence of gene methylation in OSCC surgical margin
Table 5 The frequency of gene
promoter methylation in head and
neck squamous cell carcinoma
cell lines
Gene Methylation status Frequency (%) Gene Methylation status Frequency (%)
CXXC4 M 17.2 HHIP M 27.8
M/U 22.8 M/U 30.5
U 60 U 41.7
DACT2 M 11.4 ZIC1 M 88.9
M/U 14.3 M/U 14.3
U 74.3 U 2.8
HDPR1 M/U 5.7 ZIC4 M 22.2
U 94.3 M/U 47.2
FBXW11 U 100 U 30.6
PTCH1 U 100 SUFU U 100
M full gene methylation, M/U partial methylation of gene, U complete lack of gene methylation
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did not show any statistically significant correlation
with clinicopathological variables. However, the MI
value was higher in the case of patients who developed
second primary tumors. Although such an association
was noted, it has to be considered dubious since there
were only two patients in the studied group who
developed a second primary tumor during follow-up
observation.
Discussion
Head and neck cancers are preventable tumors which develop
mostly due to prolonged exposure to cigarette smoke and
alcohol or HPV infection. In many cases, the tumor is diag-
nosed at a late stage when even aggressive treatment frequent-
ly fails to provide positive effects what results in low relapse-
free and overall survival rates in patients with regional and
distant head and neck carcinoma. Only recently, molecularly
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Fig. 1 Representative electrophoregrams for the analysis of CXXC4,
DACT2, FBXW11, HDPR1, HHIP, PTCH1, SUFU, ZIC1, and ZIC4
methylation by methylation-specific PCR using starters specific for the
methylated sequence (M) and starters specific for the unmethylated
sequence (U) in head and neck squamous cell carcinoma cell lines and
control DNA samples: HOK DNA isolated from healthy oral
keratinocytes, MET completely methylated human DNA, WBC DNA







































































Fig. 2 Relative expression levels of CXXC4, DACT2, and HHIP in
HNSCC cell lines. The relative level of transcript was calculated as fold
difference in relation to the expression in normal human keratinocytes
(where expression was adopted as equal 1). The range of relative gene
expression among cell lines (minimum and maximum values) and the
mean level of relative expression (indicated in the graphs by the arms
and the green box, respectively) in cell lines characterized by complete
gene methylation (M), partial methylation (M/U), or lack of methylation
(U) is shown
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receptor) inhibitors have been applied with moderate out-
comes in HNSCC indicating the need for the search of other
therapeutic strategies. The increasing understanding of the
molecular landscape in HNSCC points to several signaling
pathways as drivers of the oncogenic transformation.
Among those pathways, Wnt and Shh signaling seem espe-
cially interesting because of the possible association between
their deregulation and disease progression. Infrequent muta-
tions of members of these pathways and evidence of epigenet-
ic silencing of their negative regulators stimulate the focus on
the epigenetic mechanisms of modulation of the activity of
these pathways in HNSCC.
Previous studies have shown that the enhanced transcrip-
tional activity of β-catenin which is a marker of the activated
canonical Wnt signaling is causally related to increased cell
proliferation, migration, and epithelial-to-mesenchymal tran-
sition in HNSCC [9, 10]. Thus, the inhibition of β-catenin
resulted in diminished cell growth and motility [19]. The
hypermethylation of such negative regulators of Wnt pathway
as SFRP1–5, DKK1–3, WIF1, DACH1, and PPP2R2B may
significantly contribute to pathway activation and was fre-
quently observed in HNSCC [15–18]. Moreover, both the
increased expression of pathway components and the methyl-
ation of several antagonists correlated with worse prognosis.
Based on these previous findings that the methylation of Wnt
antagonists may have diagnostic significance, we decided to
analyze the methylation of other genes (CXXC4, DACT2,
HDPR1, FBXW11) which were not studied in this context in
HNSCC. Wnt signaling is antagonized by DACT2 and
HDPR1 proteins due to their ability to bind Disheveled and
thus prevent the destabilization of the β-catenin inhibitory
complex. The methylation ofDACT2was previously reported
in lung and also in gastric and thyroid cancers where it corre-
lated with tumor differentiation and invasion [32, 36, 37]. On
the other hand, HDPR1 (DACT1) was downregulated by
DNA methylation in breast or hepatocellular carcinoma [33,
38] and its downregulation was associated with poor progno-

















Fig. 3 Representative electrophoregrams for the analysis of CXXC4,
DACT2, HHIP, ZIC1, and ZIC4 methylation by methylation-specific
PCR using starters specific for the methylated sequence (M) and starters
specific for the unmethylated sequence (U) in laryngeal tumor samples
(patients no. 78, 79, 82, 83, 113) and control DNA samples: MET
completely methylated human DNA, WBC DNA derived from white
blood cells of healthy blood donors
Table 6 The frequency of gene
promoter methylation in tumor
and resection margin of HNSCC
patients
CXXC4 (%) DACT2 (%) HHIP (%) ZIC1 (%) ZIC4 (%)
LSCC 36.6 96.7 90 86.7 78.6
OSCC 10 53 62.5 100 73.2
OSCC margin 5.9 39.4 40 90 55.5
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Recently, it has been reported that both DACT1 and DACT2
are methylated in oral squamous cell carcinoma [41]. CXXC4
encodes Idax protein which also antagonizesWnt signaling by
interacting with Disheveled. Its epigenetic downregulation led
to the activation of Wnt signaling and was associated with
poor outcome in gastric cancer patients [42]. FBXW11 en-
codes one of the components of the complex responsible for
the ubiquitylation of β-catenin leading to its subsequent deg-
radation, and to our knowledge, the methylation of this gene
has not been studied in cancer so far, but the promoter region
of this gene contains a CpG island which possibly may be-
come methylated. In our current study, the methylation of
HDPR1 was marginal in the HNSCC cell lines; thus, it was
not further investigated in the group of HNSCC patients.
Similarly, we did not detect the methylation of the promoter
region of FBXW11 in any of the tested HNSCC cell lines and
thus did not investigate it further. On the other hand, we have
observed that DACT2 is frequently methylated in both the
cells lines and head and neck carcinomas while CXXC4 is
methylated to a lesser extent. Moreover, their methylation is
not observed in normal epithelial cells derived from healthy
subjects. However, the methylation of DACT2 or CXXC4 did
not significantly correlate with the clinicopathological fea-
tures of the patients.
Few studies investigated the epigenetic regulation of Shh
signaling in head and neck carcinomas; thus, we aimed to
assess whether known negative regulators of this pathway
(HHIP, PTCH1, SUFU, ZIC1, ZIC4) undergo methylation in
HNSCC. HHIP inhibits Shh signaling by sequestering Hh
ligands which then cannot activate the pathway, and its epige-
netically mediated downregulation was observed in gastroin-
testinal, hepatocellular, and pancreatic tumors [43–46].
PTCH1 blocks pathway activity in non-stimulated cells, and
its loss due to methylation was observed in breast and gastric
cancers and colorectal precancerous lesions [35, 46–48].
SUFU blocks the pathway by sequestering Gli transcription
factors in the cytoplasm, and to our knowledge, its methyla-
tion has not been studied in cancer so far. ZIC1 and ZIC4
antagonize the transcriptional activity of Gli. Previous studies
have shown that ZIC1 is frequently methylated in colorectal,
hepatocellular, and gastric cancers [49–51] while the methyl-
ation of ZIC4 was observed in bladder cancer [52]. In our
study, we have found lack of methylation of PTCH1 or
SUFU and frequent methylation of HHIP, ZIC1, and ZIC4 in
HNSCC. The observed lack of methylation of PTCH1 is in
contrast to a recent finding where restriction analysis of pro-
moter methylation showed that this gene is methylated in
many dysplastic lesions and nearly half of HNSCC cases
[53]. Methodological differences may be one possible source
of this discrepancy. Another study reported that ZIC4 is meth-
ylated in a quarter of HNSCC cases [54]. To our knowledge,
the methylation of HHIP has not been studied in HNSCC;
however, it was reported that the expression of the encoded
protein is lost in the majority of oral squamous cell carcinomas
[55]. Thus, our observation that HHIP undergoes methylation
may partly explain the mechanism of this loss in head and
neck cancers. Importantly, ZIC4methylation in tumors signif-
icantly correlated with lymph node invasion implicating that it
might be considered a prognostic biomarker. Assuming that
ZIC4 methylation leads to the upregulation of Gli1 signaling,
it may be hypothesized that it would contribute to the induc-
tion of epithelial-to-mesenchymal transition what subsequent-
ly results in increased cell motility and invasion. Indeed, the
enhancement in Shh-Gli1 signaling induced migration of pan-
creatic cancer cells [56, 57].
Table 7 The concordance of gene promoter methylation in tumor and
resection margin of OSCC patients
CXXC4 (%) DACT2 (%) HHIP (%) ZIC1 (%) ZIC4 (%)
T+ R+ 0 31 23.7 89.5 51.4
T+ R− 5.9 17.2 36.8 10.5 22.8
T− R+ 5.9 10.3 18.4 0 5.7
T− R− 88.2 41.4 21 0 20






























Fig. 4 Overall survival estimated by ZIC4 methylation detected in
tumors of oral (OSCC) and laryngeal (LSCC) cancer patients. M
patients showing ZIC4 methylation; U patients showing lack of ZIC4
methylation
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Epigenetic studies using DNA methylation-based markers
frequently indicated that the use of a panel of genes has stron-
ger diagnostic significance in comparison to single gene test-
ing. In this regard, the panel consisting of CXXC4, DACT2,
HHIP, ZIC1, and ZIC4 is a promising starting point for the
development of a prognostic epimarker panel based on the
finding that the MI value in tumor samples moderately corre-
lated with the overall time of survival in the subgroup of 18
OSCC patients who died of the disease. Interestingly, the ob-
served MI value in the surgical margin was higher in the case
of OSCC patients who developed second primary tumors.
Although this should be interpreted with great caution due to
a low number of patients who developed second primary tu-
mor during follow-up, this would be in agreement with the
field carcinogenesis model which assumes that a diversity of
molecular changes is detectable in a broad field of affected
mucosa what may predispose cells to further neoplastic trans-
formation [58, 59]. In line with this model, epigenetic changes
were observed not only in tumor sections but also in macro-
scopically normal surgical margin. The presence of epigenetic
aberrations in surgical margin and distant mucosa in HNSCC
is well documented [16, 60, 61]. These changes may consti-
tute both part of the field of preneoplastic molecular alter-
ations and be related to the presence of single neoplastic cells
which are usually not detected under standard histopatholog-
ical examination [61].
In summary, we report that CXXC4, DACT2, HHIP, ZIC1,
and ZIC4 are methylated in head and neck squamous cell car-
cinomas. These findings corroborate that the activation of Wnt
signaling in HNSCC is related to epigenetic silencing of the
negative regulators of this pathway. Moreover, the results of
our study indicate that the same mechanism of activation may
operate in the case of Shh signaling. In this regard, functional
studies should follow to investigate whether epigenetic modu-
lators may inhibit Wnt or Shh signaling due to the reactivation
of expression of pathway antagonists. Additionally, we con-
clude that the methylation of ZIC4 may be considered a new
prognostic marker in HNSCC. Further investigations should
determine the detailed diagnostic significance of methylation
of ZIC4, HHIP, and DACT2 in head and neck carcinomas.
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